Plasminogen activator inhibitor-1 promoter 4G/5G genotype is not a risk factor for myocardial infarction in a Japanese population

Blood Coagulation and Fibrinolysis

Volumn 9, Issue 2, 1998, Pages 201-204

  Sugano, T ^a   Tsuji, H ^a   Masuda, H ^a   Nakagawa, K ^a   Nishimura, H ^a   Kasahara, T ^a   Yoshizumi, M ^b   Nakahara, Y ^b   Kitamura, H ^b   Yamada, K ^b   Yoneda, M ^b   Maki, K ^b   Tatsumi, T ^b   Azuma, A ^a   Nakagawa, M ^b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Department of Internal Medicine Ohmi Hachiman City Hospital   (Japan)

Author keywords

4G 5G genotype; Myocardial infarction; PAI 1; Polymorphism; Risk factor

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC RISK; GENOTYPE; HEART INFARCTION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; POPULATION RISK; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT;

EID: 15144343125     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199803000-00013     Document Type: Article

References (11)

1. Wiman B, Hamsten A. Impaired fibrinolysis and risk of thromboembolism. Prog Cardiovasc Dis 1991; 34: 179-192.
2. Hamstcn A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N EnglJ Med 1985; 313: 1557-1563.
3. Eriksson P, Kallin B, Van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-1855.
4. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude Cas Témoins de l'Infarctus du Mycocardc. Thromb Haemost 1995; 74: 837-841.
5. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997; 95: 5962.
6. Kunkel LM, Smith KD, Boyer SH, Borgaonkar DS, Wachtel SS, Miller OJ, et al. Analysis of human Ychromosomc-specific reiterated DNA in chromosome variants. Proc Natl Acad Sci USA 1977; 74: 1245-1249.
7. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989; 5: 874-879.
8. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM . The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Cbem 1993; 268: 10739-10745.
9. Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vase Biol 1997; 17: 33-37.
10. Burzotta F, Di Castelnuovo A, Amore C, D'Orazio A, Donati MB, lacoviello L. 4G/5G polymorphism in the promoter region of the PAI-1 gene is not a risk factor for familial myocardial infarction in subjects over 45 years. Thromb Haemost 1997; 78: 1294-1295.
11. Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995; 74: 842-847.